Posted on May 18, 2019 by Sitemaster
We have noted several times in the past that, at least to date, compared to the results shown by the PD-1 and PD-L1 checkpoint inhibitors in the treatment of cancers like lung cancer, kidney cancer, and melanoma, there has been little evidence of the value of these agents in the treatment of advanced prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: atezolizumab. Keytruda, HSPC, mCRPC, nivolumab, Opdivo, PD-1, PD-L1, pembrolizumab, Tecentriq | 7 Comments »
Posted on March 29, 2019 by Sitemaster
We have heard a lot about treatment with checkpoint inhibitors over the past two or three years. When they work well, they can work very well indeed, but these drugs come with significant risk for side effects, and some of those side effects can be very serious. … READ MORE …
Filed under: Uncategorized | Tagged: checkpoint, CTLA4, immunotherapy, inhibition, PD-1, PD-L1, risk | 1 Comment »
Posted on September 5, 2018 by Sitemaster
A newly published paper by an international group of investigators has given us some further insight in to the roles of immunotherapeutic agents in the treatment of at least a subset of men with advanced forms of prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: defect, immunotherapy, mismatch, nivolumab, PD-1, pembrolizumab, repair | Leave a comment »
Posted on July 14, 2016 by Sitemaster
New immunotherapeutic drugs known as PD-1 inhibitors (drugs like nivolumab/Optivo and pembrolizumab/Keytruda) have shown some remarkable effects in the treatment of advanced forms of cancer like melanoma and some forms of lung cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, efficacy, inhibitor, outcome, PD-1 | Leave a comment »
Posted on August 25, 2014 by Sitemaster
A company called Advaxis is planning to test a new form of prostate cancer immunotherapy (ADXS-PSA) in combination with an investigational drug called pembrolizumab (an anti-PD-1 immune checkpoint inhibitor) in men with previously treated, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADXS-PSA, castration-resistant, immunotherapy, mCRPC, metastatic, PD-1, pembrolizumab | 6 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 